MXPA05007237A - Medicamentos anticancer. - Google Patents

Medicamentos anticancer.

Info

Publication number
MXPA05007237A
MXPA05007237A MXPA05007237A MXPA05007237A MXPA05007237A MX PA05007237 A MXPA05007237 A MX PA05007237A MX PA05007237 A MXPA05007237 A MX PA05007237A MX PA05007237 A MXPA05007237 A MX PA05007237A MX PA05007237 A MXPA05007237 A MX PA05007237A
Authority
MX
Mexico
Prior art keywords
group
formula
compound
alkyls
individually
Prior art date
Application number
MXPA05007237A
Other languages
English (en)
Spanish (es)
Inventor
Daniel L Flynn
Peter A Petrillo
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Priority claimed from PCT/US2003/041425 external-priority patent/WO2004060305A2/en
Publication of MXPA05007237A publication Critical patent/MXPA05007237A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
MXPA05007237A 2002-12-31 2003-12-26 Medicamentos anticancer. MXPA05007237A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43748702P 2002-12-31 2002-12-31
US43741502P 2002-12-31 2002-12-31
US43730402P 2002-12-31 2002-12-31
US43740302P 2002-12-31 2002-12-31
US46380403P 2003-04-18 2003-04-18
US10/746,607 US7279576B2 (en) 2002-12-31 2003-12-24 Anti-cancer medicaments
PCT/US2003/041425 WO2004060305A2 (en) 2002-12-31 2003-12-26 Anti-cancer medicaments

Publications (1)

Publication Number Publication Date
MXPA05007237A true MXPA05007237A (es) 2007-11-15

Family

ID=32931750

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007237A MXPA05007237A (es) 2002-12-31 2003-12-26 Medicamentos anticancer.

Country Status (4)

Country Link
US (1) US7279576B2 (US07279576-20071009-C00185.png)
JP (1) JP2006519765A (US07279576-20071009-C00185.png)
MX (1) MXPA05007237A (US07279576-20071009-C00185.png)
TW (1) TW200505455A (US07279576-20071009-C00185.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
EA019385B1 (ru) * 2006-01-30 2014-03-31 ТРАНСТЕК ФАРМА ЭлЭлСи ЗАМЕЩЕННЫЕ ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ РТРазы
JP2010518014A (ja) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な2−アミノピリジン誘導体
WO2008151183A1 (en) * 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8367686B2 (en) * 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
WO2008153974A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
CN102131807B (zh) 2008-07-23 2013-11-20 沃泰克斯药物股份有限公司 吡唑并吡啶激酶抑制剂
EP2328896B1 (en) 2008-07-23 2013-10-23 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009279611A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
MX2011011653A (es) 2009-05-06 2012-01-20 Vertex Pharma Pirazolopiridinas.
WO2011094290A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
MX2012008644A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasa de pirazolopiridinas.
JP2013518113A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピラジンキナーゼ阻害剤
WO2016205418A1 (en) 2015-06-15 2016-12-22 Asana Biosciences, Llc Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
PL3902547T3 (pl) 2018-12-28 2024-02-26 Deciphera Pharmaceuticals, Llc Inhibitory CSF1R do stosowania w leczeniu nowotworu złośliwego
MX2021013661A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
TW202108574A (zh) 2019-05-10 2021-03-01 美商迪賽孚爾製藥有限公司 雜芳基胺基嘧啶醯胺自噬抑制劑及其使用方法
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
CA3163051A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971307A (en) 1961-03-02 1964-09-30 Wellcome Found 5-anilinopyrimidines
GB1127875A (en) 1967-03-23 1968-09-18 Parke Davis & Co 4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
DE2156343A1 (de) 1970-11-13 1972-05-18 Ici Ltd Aromatische Polymere und Verfahren zu deren Herstellung
CH565887A5 (US07279576-20071009-C00185.png) 1972-08-22 1975-08-29 Ciba Geigy Ag
FR2337554A1 (fr) 1976-01-08 1977-08-05 Buzas Andre Nouveaux derives de la pyrazolidinedione
FR2396549A2 (fr) 1977-07-06 1979-02-02 Buzas Andre Nouveaux derives de la pyrazolidinedione
US4256758A (en) 1979-06-11 1981-03-17 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4298743A (en) 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4296237A (en) 1979-09-11 1981-10-20 Merck & Co., Inc. 4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
US4432992A (en) 1979-11-05 1984-02-21 Merck & Co., Inc. 4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4366189A (en) 1979-12-21 1982-12-28 Ciba-Geigy Corporation 4-Heterocyclyl-4'-vinylstilbenes
JPS5915247A (ja) 1982-07-16 1984-01-26 Mitsubishi Paper Mills Ltd 画像形成方法
JPS59177557A (ja) 1983-03-28 1984-10-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
AU606808B2 (en) 1988-06-29 1991-02-14 Otsuka Pharmaceutical Factory, Inc. Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
GB9012936D0 (en) 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
US5254715A (en) 1990-11-07 1993-10-19 Warner-Lambert Company Aminosulfonyl carbamates
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
DE4302702A1 (de) 1993-02-01 1994-08-04 Bayer Ag Arylaminosulfonylharnstoffe
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
DE4337847A1 (de) 1993-11-05 1995-05-11 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
AU1108395A (en) 1993-12-07 1995-06-27 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
DE4343831A1 (de) 1993-12-22 1995-06-29 Magyar Tudomanyos Akademia Substituierte Sulfonylharnstoffe
DE4414840A1 (de) 1994-04-28 1995-11-02 Bayer Ag Substituierte Phenylaminosulfonylharnstoffe
DK0765314T3 (da) 1994-06-15 2003-08-25 Otsuka Pharma Co Ltd Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
US5763450A (en) 1994-11-24 1998-06-09 Hoffmann-La Roche Inc. Substituted benzyl pyrimidines
US5494925A (en) 1994-12-02 1996-02-27 Sterling Winthrop Inc. 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
WO1996019477A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Plc Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists
KR100423818B1 (ko) 1995-04-24 2004-07-05 가부시키가이샤 한도오따이 에네루기 켄큐쇼 액정화합물및이를함유하는액정조성물
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
NZ324834A (en) 1995-12-28 2001-11-30 Fujisawa Pharmaceutical Co Benzimidazole derivatives and their use in reducing blood sugar or as inhibitors of PDE5 activity
GB9605945D0 (en) 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
JPH107804A (ja) 1996-06-25 1998-01-13 Japan Synthetic Rubber Co Ltd 熱硬化性樹脂組成物
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ATE230742T1 (de) 1997-03-27 2003-01-15 Great Lakes Chemical Europ 2-(2'-hydroxphenyl)-benzotriazole und ihre verwendung als lichtschutzmittel für organische polymere
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
WO1999015164A1 (en) 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
IT1295933B1 (it) 1997-10-30 1999-05-28 Great Lakes Chemical Italia 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
JP2002515476A (ja) 1998-05-15 2002-05-28 アストラゼネカ アクチボラグ サイトカインにより仲介される疾病の処置のためのベンズアミド誘導体
EP1095016B1 (en) 1998-07-08 2005-11-09 Sanofi-Aventis Deutschland GmbH Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
ES2211172T3 (es) 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
JP2002527419A (ja) 1998-10-08 2002-08-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Gsk−3阻害物質としてのピロール−2,5−ジオン類
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2000275886A (ja) 1999-03-23 2000-10-06 Konica Corp 電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
JP3972163B2 (ja) 1999-06-18 2007-09-05 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
PL366110A1 (en) 1999-08-13 2005-01-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
BR0111383A (pt) 2000-06-14 2003-05-13 Warner Lambert Co Benezenos 1,2,4-tri-substituìdos como inibidores de 15-lipoxigenase
ATE542805T1 (de) 2000-08-11 2012-02-15 Nippon Chemiphar Co Ppar-delta aktivatoren
IL155196A0 (en) 2000-10-05 2003-11-23 Fujisawa Pharmaceutical Co Benzamide derivatives and pharmaceutical compositions containing the same
JP2004530648A (ja) 2000-10-19 2004-10-07 スミスクライン・ビーチャム・コーポレイション 炎症により促進される咳の治療のためのp38阻害剤の使用
JP4386635B2 (ja) 2000-10-27 2009-12-16 ノバルティス アクチエンゲゼルシャフト 消化管間質腫瘍の処置
AU2002215218A1 (en) 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Isoxazole derivatives
JP2002226464A (ja) 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd トリアリール類縁体およびその利用
US7217533B2 (en) 2001-06-21 2007-05-15 Baylor College Of Medicine P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target
EP1281399A3 (en) 2001-08-01 2004-02-11 Warner-Lambert Company Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
RU2004121898A (ru) 2001-12-19 2006-01-20 Атеродженикс, Инк. (Us) Производные халкона и их применение для лечения заболеваний
AU2003207961A1 (en) 2002-01-16 2003-07-30 Ramot At Tel Aviv University Ltd. Compositions and their use for enhancing and inhibiting fertilization
ES2292992T3 (es) 2002-02-28 2008-03-16 F. Hoffmann-La Roche Ag Derivados de tiazol como antagonistas del receptor npy.
AU2003230692A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
US20030186221A1 (en) 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments

Also Published As

Publication number Publication date
US7279576B2 (en) 2007-10-09
US20040176395A1 (en) 2004-09-09
JP2006519765A (ja) 2006-08-31
TW200505455A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
MXPA05007237A (es) Medicamentos anticancer.
WO2004060305A2 (en) Anti-cancer medicaments
US7342037B2 (en) Anti-inflammatory medicaments
AU2007244960B2 (en) Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1836173A2 (en) Anti-inflammatory medicaments
US20070191336A1 (en) Anti-inflammatory medicaments
US20080045531A1 (en) Anti-inflammatory medicaments
JP7440572B2 (ja) デュアルmagl及びfaahインヒビター
US20060004051A1 (en) Compounds
AU2003303639A1 (en) Anti-cancer medicaments

Legal Events

Date Code Title Description
FA Abandonment or withdrawal